BioMarin Stock Hits New 52-Week High (BMRN)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- BioMarin Pharmaceuticals (Nasdaq: BMRN) hit a new 52-week high Tuesday as it is currently trading at $53.57, above its previous 52-week high of $53.45 with 447,398 shares traded as of 12:45 p.m. ET. Average volume has been 1.6 million shares over the past 30 days.

BioMarin has a market cap of $6.38 billion and is part of the health care sector and drugs industry. Shares are up 4.8% year to date as of the close of trading on Monday.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates BioMarin as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and feeble growth in the company's earnings per share. You can view the full BioMarin Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Trump's FDA: A Friendlier Biotech Sheriff

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

3 Fearless Predictions for the Second Half